Why Is Editas (EDIT) Up 40% Since Last Earnings Report?

Company Overview - Editas Medicine (EDIT) shares have increased by approximately 40% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the catalysts affecting the stock [1] Earnings Estimates - Estimates for Editas have trended downward in the past month, with the magnitude of these revisions being net zero [2][4] - Editas currently holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the upcoming months [4] VGM Scores - Editas has an average Growth Score of C, a Momentum Score of A, and a Value Score of F, placing it in the bottom 20% for the value investment strategy [3] - The aggregate VGM Score for Editas is D, which is relevant for investors not focused on a single strategy [3] Industry Performance - Editas is part of the Zacks Medical - Biomedical and Genetics industry, where Mirum Pharmaceuticals, Inc. (MIRM) has seen an 8.2% gain over the past month [5] - Mirum Pharmaceuticals reported revenues of $111.58 million for the last quarter, reflecting a year-over-year increase of 61.2% [6] - Mirum's expected loss for the current quarter is $0.32 per share, which is a year-over-year improvement of 38.5% [6] - Mirum Pharmaceuticals also holds a Zacks Rank 3 (Hold) and has a VGM Score of B [7]